Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation
Authors:
- Gregory Y.H. LipGLGregory Y.H. Lip
Abstract
No abstract availableKeywords
Funding Information
- Bayer HealthCare
- AstraZeneca
- Boehringer
- Bayer
- Pfizer/BMS
- Biotronic
- Astellas
- Sanofi
- Cardiome
- Merck
This publication has 71 references indexed in Scilit:
- Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)American Heart Journal, 2010
- Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial FibrillationJournal of the American Society of Nephrology, 2009
- Kidney Function Influences Warfarin Responsiveness and Hemorrhagic ComplicationsJournal of the American Society of Nephrology, 2009
- Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial FibrillationCirculation, 2009
- Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2008
- Major Bleeding in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Decreased Glomerular Filtration Rate Is a Risk Factor for Hemorrhagic But Not for Ischemic StrokeStroke, 2007
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?International Journal of Cardiology, 2003
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991